John Fairbanks, diagnosed with AL Amyloidosis, underwent CAR-T cell therapy as part of a clinical trial, achieving complete remission and improved organ function. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. "Well I started this battle, and I call it a battle, in 2022," Fairbanks said. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NX 201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment”

Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. To stream KVUE on your phone, you need the KVUE app. ... MANSFIELD, Texas — John Fairbanks knows a thing or two about cars. His pride and joy is a meticulously restored bright red 1967 Ford Mustang Fastback, a classic he rebuilt from the frame up. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NXC-201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment | kvue.com”

Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. Anderson said the results seen in the clinical trial have been striking, with about 95% of patients achieving complete remission. To stream WFAA on your phone, you need the WFAA app. ... MANSFIELD, Texas — John Fairbanks knows a thing or two about cars. His pride and joy is a meticulously restored bright red 1967 Ford Mustang Fastback, a classic he rebuilt from the frame up. But when Fairbanks faced a disease that threatened his life, it was another kind of "car" that would make the difference. Fairbanks became part of a clinical trial testing CAR-T cell therapy as a treatment for amyloidosis. Fairbanks was diagnosed with AL Amyloidosis, a rare and potentially deadly disease in which abnormal proteins accumulate in the body's organs, damaging vital systems such as the heart, liver and kidneys. "This therapy called NX 201 at the moment and is a form of a CAR-T cell therapy.

Original title: “'Unreal': North Texas man in remission after experimental treatment | wfaa.com”

systemic light chain amyloidosis presenting as jejunal perforation

Original title: “Systemic light chain amyloidosis presenting as jejunal perforation.”

I went into amyloidosis research in 1999 as a very naïve nephrologist who wanted to do clinical-based research in multisystem diseases... I went into amyloidosis research in 1999 as a very naïve nephrologist who wanted to do clinical-based research in multisystem diseases. I was very lucky to coincide with a period of huge advances spanning the understanding of pathogenesis to innovations in treatment. A drug be approved and still take years to reach a patient because the health economics case for an ultra-rare, high-cost therapy is hard to build. That gap between ‘licensed’ and ‘actually prescribable’ is, in my view, the bit that deserves far more attention than it currently gets. The nicest opportunity, I think, is international collaboration by pooling patients, sharing registries, and treating a rare disease trial as a genuinely global project. The way modern healthcare is structured is not always helpful in recognising multisystem disease. Tingling hands go to the neurologist or surgeon, breathlessness to the cardiologist, and fatigue gets blamed on getting older. All too often, each specialist offers a reasonable but wrong explanation, and that leaves the patient trying to connect the pieces. The best solution should not ask any one clinician to become an expert in all rare multisystem diseases. Over my career, AA amyloidosis has changed from being a relatively frequent finding to becoming a genuinely rare cause of renal amyloid. This reflects advances in the control of chronic inflammation in general, particularly the widespread introduction of highly effective biologic therapies into rheumatology practice. As a result, we now see very few cases of AA amyloidosis complicating inflammatory arthritis or autoinflammatory disease.

Original title: “Transforming Amyloidosis Care: An Interview with Helen Lachmann - European Medical Journal”

cardiac screening of amyloid ttr pathogenic variant carriers complementary value of echocardiographic global longitudinal strain imaging and bone scintigraphy

Original title: “Cardiac screening of amyloid TTR pathogenic variant carriers: complementary value of echocardiographic global longitudinal strain imaging and bone scintigraphy.”

cystic fibrosis associated amyloid a amyloidosis a rare but devastating complication with poor prognosis

Original title: “Cystic fibrosis-associated amyloid a amyloidosis: a rare but devastating complication with poor prognosis.”

amyloidosis cardiac and neurologic involvement

Original title: “Amyloidosis: Cardiac and Neurologic Involvement.”

efficacy and safety of bcma targeted therapies in relapsed or refractory al amyloidosis a descriptive pooled analysis

Original title: “Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.”

fluorine 18 florbetapir positron emission tomography unmasks amyloidosis with equivocal technetium 99m pyrophosphate findings driven by a novel transthyretin variant

Original title: “Fluorine-18 florbetapir positron emission tomography unmasks amyloidosis with equivocal technetium-99m pyrophosphate findings driven by a novel transthyretin variant.”

acute kidney injury with interstitial hemorrhage in renal heavy chain amyloidosis a clinicopathologic case report

Original title: “Acute kidney injury with interstitial hemorrhage in renal heavy chain amyloidosis: a clinicopathologic case report.”

cryo em reveals structural variability of apolipoprotein a i amyloid fibrils across organs mutations and clinical presentations

Original title: “Cryo-EM reveals structural variability of apolipoprotein A-I amyloid fibrils across organs, mutations, and clinical presentations.”

systemic apolipoprotein c iii amyloidosis in an asian lion panthera leo persica

Original title: “Systemic apolipoprotein C-III amyloidosis in an Asian lion (Panthera leo persica).”

decade long progression of localized amyloidosis from the larynx to the nasal cavity a case report

Original title: “Decade-Long Progression of Localized Amyloidosis from the Larynx to the Nasal Cavity-A Case Report.”

localized breast amyloidosis in a previously treated breast a case report and literature review

Original title: “Localized Breast Amyloidosis in a Previously Treated Breast: A Case Report and Literature Review.”

early onset axonal pathology and amyloidosis in human brains with hematological malignances and cardiovascular diseases

Original title: “Early-onset axonal pathology and β-amyloidosis in human brains with hematological malignances and cardiovascular diseases.”

negative 99mtc tc dpd scintigraphy presence of monoclonal protein and biopsy suggestive of al amyloidosis in a patient with homozygous p ala101val transthyretin gene variant

Original title: “Negative [99mTc]Tc -DPD Scintigraphy, Presence of Monoclonal Protein and Biopsy Suggestive of AL Amyloidosis in a Patient With Homozygous p.Ala101Val Transthyretin Gene Variant.”